Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • drug pricing

    - PMLiVE

    Novo Nordisk presents new findings on semaglutide in Alzheimer’s disease

    While the trials did not meet their primary endpoints, they highlighted important biomarker findings

    - PMLiVE

    Novo Nordisk reports phase 3 data showing semaglutide reduces liver scarring

    Patients with MASH in the ESSENCE phase 3 trial show semaglutide’s potential to improve liver health

    - PMLiVE

    Pfizer and Metsera agree on merger after bidding war between Pfizer and Novo Nordisk

    The Pfizer bid was chosen by Metsera after a concern was raised about US antitrust laws regarding the Novo Nordisk offer

    - PMLiVE

    Novo Nordisk agrees to lower certain drug prices in the US

    The company's semaglutide-based weight-loss drugs will be made available in the US through Medicare and Medicaid

    - PMLiVE

    Lilly announces agreement with US government to lower patient costs

    The agreement will make insulin and obesity treatments more affordable through federal programmes and direct-to-patient channels

    - PMLiVE

    Novo Nordisk reports sales growth in 2025 as R&D pipeline advances

    Growth driven by increased sales in diabetes and obesity markets

    - PMLiVE

    AstraZeneca announces agreement with US government to reduce medicine costs

    The pharma company is the latest to offer direct-to-consumer purchasing

    - PMLiVE

    Pfizer agrees pricing and distribution deal with US government

    The agreement enables US patients to access medicines at a discount, in addition to providing Pfizer with relief from US tariffs

    - PMLiVE

    Novo Nordisk to cuts 9,000 jobs in an effort to streamline its operations

    The transition will help the company meet the rising global demand in the obesity market

    - PMLiVE

    Novo Nordisk’s Alhemo approved by FDA for expanded haemophilia use

    The rare bleeding disorder affects approximately 800,000 people globally

    - PMLiVE

    Novo Nordisk appoints Maziar Mike Doustdar as president and CEO

    Doustdar has most recently been serving as Novo’s executive vice president of international operations

    - PMLiVE

    Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership

    The companies will launch four development programmes for potential small molecule therapies

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links